Alzheimer's disease drug development pipeline: 2017

INTRODUCTION: There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. METHODS: We assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, Jeffrey, Lee, Garam, Mortsdorf, Travis, Ritter, Aaron, Zhong, Kate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651419/
https://www.ncbi.nlm.nih.gov/pubmed/29067343
http://dx.doi.org/10.1016/j.trci.2017.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651419/
https://www.ncbi.nlm.nih.gov/pubmed/29067343
http://dx.doi.org/10.1016/j.trci.2017.05.002

Ejemplares similares